Kornimate/medical-research-clean huggingface dataset:
the effects of a group-based gaze training intervention for children with developmental coordination disorder

Conditions: Developmental Coordination Disorder

Summary: the aim of this study was to integrate a gaze training intervention (i.e., quiet eye training; qet) that has been shown to improve the throwing and catching skill of children with developmental coordination disorder (dcd), within an approach (i.e., group therapy) that might alleviate the psychosocial influence of these motor skill deficits.

children with dcd will be randomly split into either qet group or a technical training (tt). the tt group will be given movement-related instructions via video, relating to the throw and catch phases, while the qet group will also be taught to fixate a target location on the wall prior to the throw (qe1) and to track the ball prior to the catch (qe2). each group will take part in a 4- week, group therapy intervention and measurements of qe duration obtained from a mobile eye tracking system and catching performance are to be taken before and after training, and at a 6-week delayed retention test. parental feedback on psychosocial and motor skill outcomes will also be collected at delayed retention.

Eligibility criteria:
inclusion criteria: * prior diagnosis of developmental coordination disorder or suspected to have dcd * scores below the 5th percentile on the mabc-2 (movement assessment battery for children-2) * be of normal intelligence (assessed through parent/teacher feedback) * no neurological disorder * normal of corrected-to-normal vision exclusion criteria: * score over 5th percentile on the mabc-2 * suffers from a neurological disorder * below average intelligence * any visual impairment

Keywords: quiet eye training visual attention
uses of cmr in detection of left atrial thrombus

Conditions: Left Atrial Thrombosis

Summary: the incidence of rheumatic heart diseases have not declined in our population .rheumatic heart diseases, often neglected by media and policy makers, is a major burden in developing countries where it causes most of the cardiovascular morbidity and mortality in young people, leading to about 250000 deaths per year worldwide. mitralstenosis is one of the most common complications of rheumatic heart diseases in our community. a treatment of choice in suitable cases is percutaneous mitral commissurotomy .preoperative evaluation for percutaneous mitral commissurotomy typically requires trans-esophageal echocardiogram (tee) for the presence of la thrombus. tee is currently considered the gold standard for la thrombus detection given its favorable sensitivity and specificity . with recent advances,cmris now becoming another reliable diagnostic method for evaluation of thrombus in the left atrium, particularly when delayed imaging is performed. whereas tee is a semi-invasive procedure, cmris totally non-invasive . effectiveness of left ventricular thrombus detection by cmr has been validated, and it is now becoming a preferred imaging modality for evaluation of left ventricular thrombus . moreover, in patients undergoing pulmonary vein isolation,cardiac magnetic resonance was validated against tee for la \& left atrial appendage . to our knowledge, there are few data regarding the utility of cardiac magnetic resonance for detection of la thrombus in patients undergoing percutaneous mitral commissurotomy.

patients with mitral stenosis that admitted in assiut university hospital -cardiovascular department for doing percutaneous mitral commissurotomy will undergo trans-esophageal echo and cardiac magnetic resonance for detection of left atrial thrombus and left atrial appendage thrombus. investigators will compare the result of cardiac magnetic resonance with the results of trans-esophageal echo for seen the sensitivity and specificity of cardiac magnetic resonance in compare to trans-esophageal echo who is the gold standard imaging for detection of left atrial and left atrial appendage thrombus.data will be presented as mean ± standard deviation for continuous variables and frequency for categorical variables. * patients with and without thrombus will be compared using independent (unpaired) student t test for continuous variables and the fisher exact test for categorical variables, or their non-parametric equivalents, after testing the data for normality. * diagnostic performance of each cmr component will be calculated in the standard manner.

Eligibility criteria:
inclusion criteria: * severe mitral stenosis . * significant dyspnea. * favorable anatomical characteristics for percutaneous mitral commissurotomy as assessed by trans-thoracic echo. exclusion criteria: * critically ill patients including hemo-dynamically unstable patient. * implanted pacemakers/cardiac defibrillators and other electronic implants. * cerebral aneurysm clips. * pregnancy. * significant renal impairment
predictors of atrial fibrillation recurrence after ablation using pentaray catheter

Conditions: Atrial Fibrillation Ablation Using PENTARAY Catheter

Summary: carto represent a new way of 3d electroanaromic mapping for af which has improved safety and success rate of af ablation compared with other conventional methods of af ablation as it provide accurate visualization of atrial anatomy and identification of atrial substrate properties for catheter ablation of atrial arrythmias which ensure good ablation with decreased incidence of recurrence of af.


Eligibility criteria:
inclusion criteria: * patient with paroxismal af who are eligible for af ablation * patient resistant to medical treatment exclusion criteria: * patient with other types of arrythmias * patient with prothetic valves * patient with valvular af
lornoxicam vs. paracetamol after lower abdominal surgery

Conditions: Postoperative Pain

Summary: background: the aim of this prospective, randomized, double-blind study is to determine the most effective supplemental analgesic, paracetamol or lornoxicam for postoperative pain relief after lower abdominal surgery. methods: sixty patients scheduled for lower abdominal surgery under general anesthesia were randomly allocated to receive either isotonic saline (control group), intravenous paracetamol 1 g every 6 h (paracetamol group) or lornoxicam 16 mg then 8 mg after 12 h (lornoxicam group). additionally pain was treated postoperatively using morphine patient-controlled analgesia. postoperative pain scores measured by the verbal pain score (vps), morphine consumption and the incidence of side effects were measured at 1, 2, 4, 8, 12 and 24 hours postoperatively.


Eligibility criteria:
inclusion criteria: * lower abdominal surgery exclusion criteria: * body weight more than 150% of their ideal body weight * history of significant cardiac, pulmonary, renal, hepatic or hematological disease; chronic drug or alcohol abuse; hypersensitivity to any of the studied drugs; bronchial asthma; gastritis or peptic ulcer; and pregnancy * patients who received any analgesic drug a day before surgery

Keywords: lower abdominal surgery paracetamol lornoxicam morphine
impact on the length of stay in incentive spirometry and pain in the decompensation of sickle cell disease: .

Conditions: Sickle Cell Disease; Pediatric

Summary: in this prospective observational study among sickle cell children aged 7 to 17 years, who face many experience of pain, pain will be assessed during incentive spirometry sessions. then a relation between, inspiratory volume, pain and the length of hospital stay will be identified . currently, there is no scientific data regarding the correlation between acute pain during vaso-occlusive crisis, incentive spirometry and the impact on length of hospital stay. in fact, physiotherapist experience's in the pediatric department suggests that the pain expressed by the child is not always correlated with inspiratory capacity. the absence of pain is one of the reasons for hospital discharge after decompensation in patients with sickle cell disease. however, no scientific study has linked incentive spirometry, pain and length of hospital stay. investigator assume that these children underestimate the real pain and its impact on breathing pattern, and presume that the maximal inspiratory volume during spirometry sessions will be a better reflect of pain than standard pain scale. the aim of this study is to show that inspiratory volume would be a better indicator of discharge from hospitalization than actual pain scales.


Eligibility criteria:
inclusion criteria: * sickle cell children aged 7 to 17 admitted to the pediatric ward * children receiving respiratory physiotherapy sessions under medical prescription * children hospitalized for more than 24 hours at the chro and benefiting from more than one physiotherapy session. * absence of opposition of one of the parents to the participation of their child in the study * absence of opposition of children able to understand the study non inclusion criteria: * sickle cell children under the age of 7 or over 17 * children with mental deficits * non-french-speaking parents * children receiving only one physiotherapy session and being hospitalized within 24 hours

Keywords: sickle cell disease incentive spirometry pain children
efficacy and tolerance of baricitinib, a jak inhibitor, in the treatment of refractory non-infectious non-anterior uveitis

Conditions: Active Non-anterior Non-infectious Uveitis

Summary: the aim of the study is to evaluate the efficacy of baricitinib, a jak1 and 2 inhibitor, in the management of non-infectious non-anterior uveitis refractory to at least one line of biotherapy (anti-tnf alpha, tocilizumab) after 6 months of treatment


Eligibility criteria:
inclusion criteria: * patient with diagnosis of non-anterior non-infectious uveitis, refractory to at least one line of biotherapy (anti-tnf alpha, tocilizumab) * need to stop biotherapy (anti-tnf alpha or tocilizumab) and conventional immunosuppressive drugs (mycofenolate mofetil, methotrexate, azathioprine, cyclosporine, interferon alpha 2a) for at least 10 days prior to the inclusion date exclusion criteria: * 1. isolated anterior uveitis. 2. infectious uveitis. 3. severe uveitis threatening the visual prognosis and requiring emergency treatment with intravenous corticosteroids. 4. initial visual acuity \> 1.3 logmar in at least one eye. 5. corneal or lens opacity that prevents fundus visualization or may require cataract surgery during the study. 6. contraindication to baricitinib (olumiant 2 and 4 mg film-coated tablets) : hypersensitivity to the active substance or to any of the excipients. 7. contraindication to mydriasis. 8. refractory glaucoma in either eye. 9. monophthalmic patient. 10. previous treatment with jak inhibitors. 11. intraocular corticosteroid injection (subconjunctival or laterobulbar) within 1 month prior to inclusion or intravitreal corticosteroid implant within 3 months prior to inclusion. 12. need for treatment with a biotherapy (anti-il6, anti-il6 receptor, anti-il1, anti-il12/il23 anti-il17, anti-baff) for extra-ocular involvement, during the entire study period. 13. treatment with oat3 inhibitors with high inhibitory potential such as probenecid, leflunomide, teriflunomide 14. 14. vaccination with a live or live attenuated vaccine within 15 days prior to inclusion 15. history of cancer within the previous 5 years, except non-metastatic squamous cell and basal cell carcinoma of the skin. 16. personal history of venous thromboembolic disease.
telmisartan (micardis) and amlodipine (norvasc) - factorial design study for the treatment of hypertension

Conditions: Hypertension

Summary: to demonstrate that micardis and norvasc when used together are more effective at lowering blood pre ssure.


Eligibility criteria:
inclusion criteria: main inclusion criteria: male and female patients \>=18 years of age with stage i or ii hypertension defined as: a mean seated cuff diastolic blood pressure \>=95 and \<=119 mmhg main exclusion criteria: exclusion criteria: 1. patient is pregnant; breast-feeding; unwilling to use birth control during the study; has secondary hypertension; severe renal dysfunction; hepatic insufficiency; stroke within the last six months; myocardial infarction, cardiac surgery, percutaneous transluminal coronary angioplasty, unstable angina or coronary artery bypass graft within the past three months; unstable or uncontrolled diabetes for the past three months defined as a glucosylates hemoglobin (hba1c) greater than ten percent ; history of angioedema or hypersensitivity related to either study drug. 2. systolic blood pressure (sbp) is greater than or equal to 180 millimeters of mercury (mmhg), diastolic blood pressure (dbp) is greater than or equal to 110 mmhg.
immunotherapy with autologous tregs in t1dm

Conditions: Type 1 Diabetes Mellitus

Summary: type 1 diabetes (t1d) is an autoimmune disease characterized by a progressive immune distruction of pancreat beta cells and deterioration of endogenous insulin secretion. regulatory t cells (treg) are fuctionally deficient in t1d, leading to the loss of immune tolerance to the islets and the initiation of an autoimmune attack. previouse studies have revealed the potential theraputic effects of autologous treg transplantation in t1d. we have modified the preparation protocol for autologous tregs. the purpose of this study is to assess the safety and effect of autologous treg therapy in patients with t1d.


Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria of t1dm based on the 2021 version of the chinese guidelines for diagnosis and treatment of type 1 diabetes; * aged 8 to 65 years; * at least one islet autoantibody positive and/or fasting c-peptide does not exceed 300pmol/l; * must be capable of providing written, signed, and dated informed consent and willing to comply with research requirements in the study. exclusion criteria: * the condition of diabetic ketoacidosis has not been controlled; * severe allergic constitution; * known or suspected tumor; * acute pancreatitis, and severe heart, liver, kidney, rheumatic immune, respiratory, nervous or infectious diseases. * suffering from gestational diabetes mellitus, single gene mutation diabetes mellitus, diabetes mellitus caused by pancreatic damage or other secondary diabetes mellitus (such as diabetes mellitus caused by cushing's syndrome, thyroid dysfunction or acromegaly, etc.); * women who are pregnant or have a pregnancy plan before and after treatment, and women who are breastfeeding. * mental illness, alcohol or drug abuse, unable to cooperate with treatment; * according to the judgment of the investigator, there are other clinical conditions that may endanger the safety of the subjects.
smart trial for buprenorphine-naloxone medication assisted treatment adherence

Conditions: Opioid-use Disorder

Summary: the purpose of this study is to compare the effectiveness of two different interventions for medication-assisted treatment (mat) adherence: contingency management (cm) and brief motivational interviewing + substance free activities + mindfulness (bsm).

the investigators seek to compare the effectiveness of these two different interventions for mat adherence by first refining and piloting cm and bsm adherence approaches, then conducting a sequential multiple assignment randomized trial (smart) to assess sequential, individual, and combined effects across mat initiation and maintenance. in order to tailor treatment to individual's needs, the study will follow a sequential multiple assignment randomized trial (smart) design: in stage 1, participants are individually randomized (1:1) to bsm or cm. adherent buprenorphine-naloxone participants complete treatment in the arm they were originally assigned to, but non-adherent participants are re-randomized (1:1) to either switch to the other intervention or add the other intervention in this part-factorial smart.

Eligibility criteria:
inclusion criteria: * present with symptoms of opioid use disorder * eligible of receipt of buprenorphine-naloxone medication as determined by study doctor * access to a telephone exclusion criteria: * under 18 years old * unable to understand spoken english

Keywords: opioid use disorder buprenorphine treatment adherence
safety, tolerability and efficacy of atl-104 in oral mucositis

Conditions: Mucositis

Summary: this purpose of this study is to investigate whether atl-104 is safe and well tolerated, and whether it shows evidence of efficacy in mucositis in patients undergoing pbsct

mucositis is a serious side effect of cancer therapy and peripheral blood stem cell transplant (pbsct) which requires appropriate and effective management. mucositis is a condition in which there is inflammation and ulceration of the mouth, throat and gut caused by damage to the mucosal barrier induced by chemo- and radiotherapy. symptoms include pain, nausea, abdominal cramping, and vomiting. this study will investigate whether atl-104, when administered as a swallowable mouthwash, is safe and well tolerated in patients undergoing pbsct and to investigate its potential to reduce the level of severity of mucositis associated with pbsct.

Eligibility criteria:
inclusion criteria: * patients with haematological malignancies undergoing chemotherapy in association with pbsct exclusion criteria: * clinically significant conditions that would exclude the patient receiving chemotherapy in association with pbsct * visible oral disease * significantly reduced platelet and neutrophil count

Keywords: mucositis peripheral blood stem cell transplant
effects of microcurrent in a cardiovascular rehabilitation home-based program

Conditions: Acute Myocardial Infarction

Summary: the aim of this study was to investigate the effects of electric stimulation (electrolipolysis) in a home-based cardiovascular rehabilitation program in patients with acute myocardial infarction

cardiovascular disease is the leading cause of death in most industrialized countries. it is widely accepted that cardiac rehabilitation has a beneficial role in the control of modifiable cardiovascular risk factors. however, these cardiovascular rehabilitation programs are scarce and only a small fraction of the population who needs has access. so, it is pertinent to the displacement of these programs to the community context. obesity has become a truly global epidemic among children and adults, as well as changing the metabolic profile: when occurs an excessive accumulation of adipose tissue (mainly central distribution) there are a set of changes / adjustments to the cardiac structure and function. the electrical stimulation of abdominal subcutaneous (electrolipolysis) is a procedure often used in physical therapy clinics to reduce waist circumference. however, the effectiveness of this intervention, the selection of parameters, and the duration of its effects in cardiac patients are not yet clarified in the literature.

Eligibility criteria:
inclusion criteria: * individuals admitted to the coronary care unit for acute myocardial infarction for more than one year; * individuals of both sexes; * ages between 40 and 75 years; * heart disease stabilized; * motivation to perform physical activity for 8 weeks; * cognitive level sufficient to understand the particulars of the study. exclusion criteria: * contraindications of micro-current (pacemaker, osteosynthesis material, tumor areas and open wounds or skin changes in the abdominal region); * pregnant at the time, in the preceding 6 months or wishing to become pregnant during the intervention period; * neurological, musculoskeletal or respiratory disorders; * individuals who are to carry out other therapies.

Keywords: cardiovascular rehabilitation home-based acute myocardial infarction obesity microcurrent
telehealth language intervention for children with autism ages 2-4 years

Conditions: Autism Spectrum Disorder

Summary: the main goal of this intervention is to increase caregivers' use of interactive play and communication strategies to improve the child's early sentence development using telemedicine and video-based feedback.

record was updated 11/2/2021 to include more detailed information about outcome measure time points. specifically, secondary outcome measures will be collected more frequently over the course of the study (i.e., at baseline \[before starting intervention\], immediate follow-up \[week 12\], and long-term follow-up \[3 months after intervention\] assessments). no changes were made to outcome measures or how they are operationalized.

Eligibility criteria:
inclusion criteria: * diagnosis of autism spectrum disorder (asd) and/or communication disorder * child speaks at least 50 single words or uses emerging word combinations * caregivers have internet availability from their home exclusion criteria: * child speaks using complex sentences * child is not within 2 to 4 years of age at time of enrollment
study of lgx818 and cetuximab or lgx818, byl719, and cetuximab in braf mutant metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: this study will assess the safety and efficacy of lgx818 when combined with cetuximab or combined with cetuximab and byl719 in patients with braf mutant metastatic colorectal cancer


Eligibility criteria:
inclusion criteria: * metastatic colorectal cancer * progression after at least one prior standard of care regimen or be intolerant to irinotecan-based regimens * life expectancy ≥ 3 months * ecog performance status ≤ 2 exclusion criteria: * symptomatic or untreated leptomeningeal disease * symptomatic brain metastasis * patients with clinically manifested diabetes * acute or chronic pancreatitis * clinically significant cardiac disease other protocol-defined inclusion/exclusion criteria may apply.

Keywords: open-label dose escalation braf inhibitor lgx818 pi3k inhibitor byl719 egfr cetuximab metastatic colorectal cancer kras braf v600
evaluation of computer-controlled local anesthesia in children - a clinical trial

Conditions: Local Anesthesia Injection Pain

Summary: the goal of this clinical trial is to learn if computer controlled local anesthetic delivery (cclad) results in lower pain during local anesthesia administration for infiltration in the buccal region of the upper jaw in patients between 6 and 16 years old who will receive a dental treatment. the main questions it aims to answer are: * does cclad result in lower self-reported pain (visual analogue scale (vas) and face pain scale-revised (fps-r)) for patients between 6 and 16 years old who need local anesthesia in the upper jaw for a dental treatment? * does ccladd result in lower observed pain (sound eye motor scale (sem)) for patients between 6 and 16 years old who need local anesthesia in the upper jaw for a dental treatment? * does cclad result in lower hearth rate (hr) and galvanic skin response (gsr) for patients between 6 and 16 years old who need local anesthesia in the upper jaw for a dental treatment? researchers will compare cclad (dentapen, septodont, france) to conventional local anesthesia infiltration with a metallic syringe to see if the infiltration is less painful in patients between 6 and 16 years old who will receive a dental treatment. participants will receive local anesthesia either with the dentapen or metallic syringe. * gsr and heart rate are measured before anesthesia, during needle insertion, at 0.3 - 0.6 - 0.9ml, and after anesthesia. * post-injection, the child provides vas scores (if 8 years or older) and fps-r (all patients). * a researcher not administering the injection determines the sem score.


Eligibility criteria:
inclusion criteria: * patients between the ages of 6 and 16 years * requiring a buccal injection with local anesthesia for dental treatment, bilaterally in the upper jaw * treatments: restorative filing, pulpotomy, extraction or a steel crown placement * at least one week between both treatments * complying with the criteria of asa i (asa classification of the american society of anaesthesiologists, 1963) * fluent in dutch * children who had a score of 3 or higher on the frankl scale exclusion criteria: * contraindications to inject local anesthesia (allergy to the liquid, ...) * patients referred because of needle phobia or behavior management problems * refusing to sign the informed consent

Keywords: dentistry pediatric local anesthesia pain